Hypertension has quietly emerged as one of Bangladesh’s most pressing public health challenges. Its growing prevalence, low treatment coverage, and rising contribution to premature deaths impose an escalating burden on both the healthcare system and the national economy.
Yet, despite the immense scale of this crisis, hypertension control continues to receive inadequate attention in national health financing and budgeting.
According to the Bangladesh NCD STEPS Survey 2022, nearly one in four adults in the country is living with hypertension. The situation is even more alarming when examined closely. The Bangladesh Bureau of Statistics’ Health and Morbidity Status Survey 2025 identifies hypertension as the leading disease among the country’s top ten health conditions.
Even more concerning, the World Health Organization’s 2025 report shows that nearly half of those living with hypertension in Bangladesh remain unaware of their condition. Among those affected, only 39% receive treatment, while just 16% are able to keep their blood pressure under control.
These figures point to a growing national health emergency. Hypertension is a major contributor to heart disease, stroke, kidney failure, and premature death.
In 2024 alone, cardiovascular diseases claimed more than 283,000 lives in Bangladesh, with hypertension contributing to over half of those fatalities.
Despite this staggering toll, the country's response remains constrained by a critical bottleneck: The lack of sustainable financing for hypertension and non-communicable disease (NCD) control.
The country’s health sector allocation has long remained around 5% of the national budget and below 1% of GDP. This investment ranks among the lowest in South Asia and far below the WHO’s recommended level of at least 15% of the national budget and 5% of GDP.
Compounding this underfunding, nearly 69% of health expenditures in Bangladesh are borne directly by individuals, placing a heavy financial burden on people living with chronic conditions that require lifelong treatment.
The neglect of NCDs within health financing is equally concerning.
Although NCDs account for nearly 71% of all deaths in Bangladesh, only 4.2% of the health budget is allocated to NCD prevention and control.
Annual per capita spending on NCDs stands at just $0.08, far below the WHO-recommended $1.50.
This widening gap between disease burden and budgetary priority can no longer continue.
Investing in hypertension prevention and control is not simply a health expenditure; it is an economic necessity. Research shows that investing in hypertension screening and treatment is highly cost-effective.
Every taka spent can bring nearly 18 times the return by reducing healthcare costs, improving productivity, and preventing costly complications such as heart attacks, strokes, kidney failure and other NCDs.
The government’s decision to provide anti-hypertensive medicines through community clinics and NCD corners is therefore both timely and commendable.
If effectively implemented, this initiative can substantially improve hypertension control, particularly for low-income and marginalized populations who often cannot afford long-term treatment.
However, without adequate and sustained financing, irregular medicine supply and treatment interruptions will continue to undermine progress, leaving millions vulnerable to severe health risks.
Hypertension is often called the “silent killer” because its damage accumulates quietly until catastrophic complications emerge. Bangladesh can no longer afford a passive response to a public health crisis of this scale.
The upcoming FY 2026-27 national budget presents a critical window of opportunity to prioritize sustainable financing for hypertension and broader NCD control through increased allocation, stronger implementation, and uninterrupted medicine supply at community clinics and upazila health complexes.
Such investment is now essential not only for protecting public health, but also for reducing inequality and securing the country’s long-term socioeconomic development.
Muhammad Ruhul Quddus and ABM Zubair are the Bangladesh Country Lead, Data for Health, Global Health Advocacy Incubator (GHAI) and the Executive Director, PROGGA (Knowledge for Progress), respectively.
